RenovoRx reports Q3 net loss of $2.1M; cash at $8.1M; Phase III interim analysis expected Q4 2022

RenovoRx, Inc.

2023-Q3 EPS reported -$0.86

Net loss of $2.1 million for Q3 2022, up from $1.5 million in Q3 2021.
Cash and short-term marketable securities of $8.1 million as of Sep 30, 2022; 9.07M shares outstanding.
G&A expenses rose to $1.3M from $0.6M, driven by post-IPO support and D&O insurance premiums.
Expects first prospective interim analysis of Phase III TIGeR-PaC trial in pancreatic cancer in Q4 2022.
Plans to launch Phase II/III trial in extrahepatic cholangiocarcinoma in Q4 2022/Q1 2023; appointed Angela Gill Nelms as COO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RenovoRx, Inc. reported the quarter ended September 30, 2022 results: net income $2.1 million.

Period: the quarter ended September 30, 2022
Net income: $2.1 million
Result: reported results

Exact text from the filing

Net loss was $2.1 million for the quarter ended on September 30, 2022, compared to a net loss of $1.5 million for Q3 ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031670

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.